Ameriprise
GCVRZ

Ameriprise’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Ameriprise’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19,209
Closed -$16K – 3815
2019
Q4 		$16K Sell
19,209
-420
-2% -$322 ﹤0.01% 3691
2019
Q3 		$11K Sell
19,629
-6,523
-25% -$3.51K ﹤0.01% 3692
2019
Q2 		$13K Sell
26,152
-1,105
-4% -$552 ﹤0.01% 3708
2019
Q1 		$12K Sell
27,257
-7,817
-22% -$3.65K ﹤0.01% 3675
2018
Q4 		$16K Sell
35,074
-712
-2% -$354 ﹤0.01% 3595
2018
Q3 		$19K Buy
35,786
+328
+0.9% +$176 ﹤0.01% 3687
2018
Q2 		$17K Buy
35,458
+30
+0.1% +$14 ﹤0.01% 3619
2018
Q1 		$15K Sell
35,428
-850
-2% -$342 ﹤0.01% 3609
2017
Q4 		$14K Sell
36,278
-176
-0.5% -$67 ﹤0.01% 3618
2017
Q3 		$13K Buy
36,454
+45
+0.1% +$17 ﹤0.01% 3657
2017
Q2 		$14K Sell
36,409
-426
-1% -$174 ﹤0.01% 3704
2017
Q1 		$16K Buy
+36,835
New +$16.2K ﹤0.01% 3592

Ameriprise's GCVRZ Position: Q1 2020 in Review

Ameriprise sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 19,209 shares — an estimated $16K sold.

Ameriprise first reported a position in GCVRZ in Q1 2017 and held it in 12 quarters. The position peaked at $19K in Q3 2018. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

  • Ameriprise reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Ameriprise sold 19,209 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $16K.
  • Ameriprise first reported a position in Sanofi Contingent Value Rights in Q1 2017 and held it in 12 quarters.
  • Ameriprise's Sanofi Contingent Value Rights position peaked at $19K in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on Ameriprise's 13F filing for Q1 2020, filed 15 May 2020.